Patent application number | Description | Published |
20100041234 | Process For Restoring Dielectric Properties - A method for preparing an interlayer dielectric to minimize damage to the interlayer's dielectric properties, the method comprising the steps of: depositing a layer of a silicon-containing dielectric material onto a substrate, wherein the layer has a first dielectric constant and wherein the layer has at least one surface; providing an etched pattern in the layer by a method that includes at least one etch process and exposure to a wet chemical composition to provide an etched layer, wherein the etched layer has a second dielectric constant, and wherein the wet chemical composition contributes from 0 to 40% of the second dielectric constant; contacting the at least one surface of the layer with a silicon-containing fluid; optionally removing a first portion of the silicon-containing fluid such that a second portion of the silicon-containing fluid remains in contact with the at least one surface of the layer; and exposing the at least one surface of the layer to UV radiation and thermal energy, wherein the layer has a third dielectric constant that is restored to a value that is at least 90% restored relative to the second dielectric constant. | 02-18-2010 |
20100151206 | Method for Removal of Carbon From An Organosilicate Material - Described herein is a method for removing at least a portion of the carbon-containing species within an organosilicate (OSG) film by treating the OSG film with a chemical, such as but not limited to an oxidizer, exposing the OSG film to an energy source comprising ultraviolet light, or treating the OSG film with a chemical and exposing the OSG film to an energy source. | 06-17-2010 |
20100152086 | Wet Clean Compositions for CoWP and Porous Dielectrics - The present invention is a formulation for wet clean removal of post etch and ash residue from a semiconductor substrate having a CoWP feature, comprising;
| 06-17-2010 |
20110212866 | WATER-RICH STRIPPING AND CLEANING FORMULATION AND METHOD FOR USING SAME - The present invention relates to water-rich formulations and the method using same, to remove bulk photoresists, post-etched and post-ashed residues, residues from Al back-end-of-the-line interconnect structures, as well as contaminations. The formulation comprises: hydroxylamine; corrosion inhibitor containing a mixture of alkyl dihydroxybenzene and hydroxyquinoline; an alkanolamine, a water-soluble solvent or the combination of the two; and at least 50% by weight of water. | 09-01-2011 |
20120295447 | Compositions and Methods for Texturing of Silicon Wafers - Pre-texturing composition for texturing silicon wafers having one or more surfactants. Methods of texturing silicon wafers having the step of wetting said wafer with a pre-texturing composition having one or more surfactants followed by a texturing step. | 11-22-2012 |
20130061882 | Cleaning Formulations and Method of Using the Cleaning Formulations - A water-rich hydroxylamine formulation for photoresist and post-etch/post-ash residue removal in applications wherein a semiconductor substrate comprises aluminum. The cleaning composition comprises from about 2 to about 15% by wt. of hydroxylamine; from about 50 to about 80% by wt. of water; from about 0.01 to about 5.0% by wt. of a corrosion inhibitor; from about 5 to about 45% by wt. of a component selected from the group consisting of: an alkanolamine having a pKa<9.0, a water-miscible solvent, and a mixture thereof. Employment of such composition exhibits efficient cleaning capability for Al substrates, minimal silicon etch while protecting aluminum for substrates comprising both materials. | 03-14-2013 |
20130130508 | Compositions and Methods for Texturing of Silicon Wafers - Texturing composition for texturing silicon wafers having one or more surfactants. Methods of texturing silicon wafers having the step of wetting said wafer with a texturing composition having one or more surfactants. | 05-23-2013 |
20130295334 | Method for Removal of Carbon from an Organosilicate Material - Described herein is a method for removing at least a portion of the carbon-containing species within an organosilicate (OSG) film by treating the OSG film with a chemical, such as but not limited to an oxidizer, exposing the OSG film to an energy source comprising ultraviolet light, or treating the OSG film with a chemical and exposing the OSG film to an energy source. | 11-07-2013 |
20130296215 | WATER-RICH STRIPPING AND CLEANING FORMULATION AND METHOD FOR USING SAME - The present invention relates to water-rich formulations and the method using same, to remove bulk photoresists, post-etched and post-ashed residues, residues from Al back-end-of-the-line interconnect structures, as well as contaminations. The formulation comprises: hydroxylamine; corrosion inhibitor containing a mixture of alkyl dihydroxybenzene and hydroxyquinoline; an alkanolamine, a water-soluble solvent or the combination of the two; and at least 50% by weight of water. | 11-07-2013 |
20140100151 | Stripping and Cleaning Compositions for Removal of Thick Film Resist - Stripping and cleaning compositions suitable for the removal of film resists include about 2-55% by weight of at least one alkanolamine or at least one morpholine or mixtures thereof; about 20-94% by weight of at least one organic solvent; and about 0.5-60% by weight water based on the total weight of the composition. | 04-10-2014 |
20140109931 | Cleaning Formulations - A composition and method for removing copper-containing post-etch and/or post-ash residue from patterned microelectronic devices is described. The removal composition includes water, a water-miscible organic solvent, an amine compound, an organic acid, and a fluoride ion source. The compositions effectively remove the copper-containing post-etch residue from the microelectronic device without damaging exposed low-k dielectric and metal interconnect materials. | 04-24-2014 |
Patent application number | Description | Published |
20080246451 | POWER SUPPLY FOR A LOAD CONTROL - A power supply adapted to be coupled in series electrical connection between an AC voltage source and an electrical load for generating a DC voltage, the power supply comprising an energy storage capacitor, the DC voltage produced across the capacitor; a charging circuit adapted to be coupled in series electrical connection between the source and the load and to conduct a load current from the source to the load, the charging circuit coupled to the energy storage capacitor for charging the energy storage capacitor; a controllably conductive device coupled in parallel electrical connection with the charging circuit and having a control input for rendering the controllably conductive device conductive, the controllably conductive device adapted to carry the load current from the source to the load when the controllably conductive device is conductive; and a triggering circuit coupled to the control input of the controllably conductive device for causing the controllably conductive device to become conductive when the energy storage capacitor has charged to a desired maximum value; wherein the charging circuit is adapted to conduct the load current from the source to the load when the controllably conductive device is non-conductive, the charging circuit imposing a low voltage drop relative to the peak value of an AC voltage of the AC voltage source, such that substantially all of the AC voltage is available to the load during the time when the controllably conductive device is non-conductive. | 10-09-2008 |
20090072775 | METHOD AND APPARATUS FOR QUIET FAN SPEED CONTROL - An AC motor speed controller includes a plurality of capacitors that may be selectively switched, by means of controllably conductive switches, into series electrical connection with an AC motor and an AC voltage source to control the speed of the motor. To change the speed of the motor, a control circuit renders a first switch conductive, in response to a first detected AC voltage zero crossing, to charge a first capacitor to a predetermined voltage. The control circuit then renders a second switch conductive, in response to a subsequent second detected AC voltage zero crossing, to charge a second capacitor to the predetermined voltage. The control circuit then renders both switches simultaneously conductive at a predetermined time after a subsequent third detected AC voltage zero crossing. The capacitors will thereby be charged to the same voltage prior to being switched into series with the motor, thereby resulting in reduced acoustic noise when changing motor speeds. | 03-19-2009 |
20100109597 | METHOD AND APPARATUS FOR QUIET FAN SPEED CONTROL - A method for controlling the speed of an AC motor by means of an AC motor speed control having a plurality of capacitors operable to be selectively coupled in parallel electrical connection, the parallel coupled capacitors operable to be coupled in series electrical connection with the AC motor, the method comprising charging the capacitors up to substantially the same predetermined voltage prior to combining the capacitors in parallel electrical connection. | 05-06-2010 |
20120261078 | MOTORIZED WINDOW TREATMENT - A motorized window treatment controls daylight entering a space through a window and includes a covering material, a drive shaft, lift cords received around the drive shaft and connected to the covering material, and a motor coupled to the drive shaft. It also includes a spring assist unit for the motor providing a torque that equals the torque provided by the weight on the lift cords at a position midway between fully-open and fully-closed positions, minimizing motor usage and conserving battery life. A photosensor for measuring the daylight outside the window and temperature sensors for measuring the temperatures inside and outside of the window may be provided. The position of the covering material is automatically controlled to save energy, or may also be controlled in response to an infrared or radio-frequency remote control. | 10-18-2012 |
20150159433 | MOTORIZED WINDOW TREATMENT - A motorized window treatment provides a low-cost solution for controlling the amount of daylight entering a space through a window. The window treatment includes a covering material, a drive shaft, at least one lift cord rotatably received around the drive shaft and connected to the covering material, and a motor coupled to the drive shaft for raising and lowering the covering material. The window treatment also includes a spring assist unit for assisting the motor by providing a torque that equals the torque provided by the weight on the cords that lift the covering material at a position midway between fully-open and fully-closed positions, which helps to minimize motor usage and conserve battery life if a battery is used to power the motorized window treatment. The window treatment may comprise a photosensor for measuring the amount of daylight outside the window and temperature sensors for measuring the temperatures inside and outside of the window. The position of the covering material may be automatically controlled in response to the photosensor and the temperature sensors to save energy, or may also be controlled in response to an infrared or radio-frequency remote control. | 06-11-2015 |
20150226001 | MOTORIZED WINDOW TREATMENT - A motorized window treatment may provide a low-cost solution for controlling the amount of daylight entering a space through a window. The window treatment may include a covering material (e.g., a cellular shade fabric or a roller shade fabric), a drive assembly for raising and lowering the covering material, and a motor drive unit including a motor configured to drive the drive assembly to raise and lower the covering material. The motorized window treatment may comprise one or more battery packs configured to receive batteries for powering the motor drive unit. The batteries may be located out of view of a user of the motorized window treatment (e.g., in a headrail or in a battery compartment). The motorized window treatment may use various power-saving methods to lengthen the lifetime of the batteries, e.g., to reduce the motor speed to conserve additional battery power and extend the lifetime of the batteries. | 08-13-2015 |
Patent application number | Description | Published |
20100022095 | Selective Etching and Formation of Xenon Difluoride - This invention relates to a process for selective removal of materials, such as: silicon, molybdenum, tungsten, titanium, zirconium, hafnium, vanadium, tantalum, niobium, boron, phosphorus, germanium, arsenic, and mixtures thereof, from silicon dioxide, silicon nitride, nickel, aluminum, TiNi alloy, photoresist, phosphosilicate glass, boron phosphosilicate glass, polyimides, gold, copper, platinum, chromium, aluminum oxide, silicon carbide and mixtures thereof. The process is related to the important applications in the cleaning or etching process for semiconductor deposition chambers and semiconductor tools, devices in a micro electro mechanical system (MEMS), and ion implantation systems. Methods of forming XeF | 01-28-2010 |
20130157435 | Materials and Methods of Forming Controlled Void - The present invention is a process for forming an air gap within a substrate, the process comprising: providing a substrate; depositing a sacrificial material by deposition of at least one sacrificial material precursor; depositing a composite layer; removal of the porogen material in the composite layer to form a porous layer and contacting the layered substrate with a removal media to substantially remove the sacrificial material and provide the air gaps within the substrate; wherein the at least one sacrificial material precursor is selected from the group consisting of: an organic porogen; silicon, and a polar solvent soluble metal oxide and mixtures thereof. | 06-20-2013 |
20140363950 | Materials and Methods of Forming Controlled Void - The present invention is a process for forming an air gap within a substrate, the process comprising: providing a substrate; depositing a sacrificial material by deposition of at least one sacrificial material precursor; depositing a composite layer; removal of the porogen material in the composite layer to form a porous layer and contacting the layered substrate with a removal media to substantially remove the sacrificial material and provide the air gaps within the substrate; wherein the at least one sacrificial material precursor is selected from the group consisting of: an organic porogen; silicon, and a polar solvent soluble metal oxide and mixtures thereof. | 12-11-2014 |
20140373713 | Pressure Swing Adsorption Process - A pressure swing adsorption process for an adsorption system having 12 adsorption beds, the process having a cycle with 5 pressure equalization steps. Background is provided for the various pressure swing adsorption cycle steps. | 12-25-2014 |
Patent application number | Description | Published |
20110021555 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORTER DOSING REGIMENS FOR TREATING ACTINIC KERATOSES - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 01-27-2011 |
20110207766 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 08-25-2011 |
20110257216 | 2 x 2 x 2 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-20-2011 |
20110257217 | 3 x 3 x 3 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-20-2011 |
20110257218 | 2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-20-2011 |
20110257219 | LOWER DOSAGE STRENGTH PHARMACEUTICAL COMPOSITIONS FORUMLATED WITH 3.75% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-20-2011 |
20110263633 | UP TO SIX WEEKS TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSES WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110263634 | LOWER DOSAGE STRENGTH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110263635 | METHOD OF TREATING ACTINIC KERATOSIS WITH 3.75% IMIQUIMOD CREAM - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110263636 | 3 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110263637 | UP TO SIX WEEKS DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 10-27-2011 |
20110319811 | COMBINATION THERAPY WITH CRYOSURGERY AND LOW DOSAGE STRENGTH IMIQUIMOD TO TREAT ACTINIC KERATOSIS - The present invention is directed to the use of complementary or combination lesion-directed therapy, such as cryosurgery, and field-directed therapy, such as low dose imiquimod topical therapy with short durations, in combination to treat actinic keratosis (“AK”). In carrying out the present invention, the lesion-directed and field-directed therapies may be applied sequentially or concomitantly, in accordance with the present invention. The novel complementary or combination AK therapy contemplated by the present invention: (1) significantly improves clearance of cryosurgery-treated Aks; (2) treats subclinical AK lesions; (3) treats those visible AK lesions in excess of that cryosurgery can actually treat in a single treatment due to, e.g., patient tolerance, provider treatment limits and/or cryosurgery cost to the patient; and (4) enhances sustained clearance overall, as compared to mono AK lesion-directed therapy. | 12-29-2011 |
20120289538 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 11-15-2012 |
20120329823 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20120329824 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20120329825 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2 methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 12-27-2012 |
20130210855 | 2 X 2 X 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 08-15-2013 |
Patent application number | Description | Published |
20100166778 | Toll-Like Receptor 3 Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 07-01-2010 |
20100254992 | ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-MCP-1 antibody having specific epitopes, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 10-07-2010 |
20110008352 | Toll-Like Receptor 3 Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 01-13-2011 |
20110236390 | IL-17A Antagonists - Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 09-29-2011 |
20120064095 | TOLL-LIKE RECEPTOR 3 ANTAGONISTS FOR THE TREATMENT OF METABOLIC AND CARDIOVASCULAR DISEASES - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 03-15-2012 |
20120237528 | Human Tissue Factor Antibody and Uses Thereof - The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs. | 09-20-2012 |
20130090457 | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 04-11-2013 |
Patent application number | Description | Published |
20090239258 | Anti-IL-6 Antibody Nucleic Acid Molecules and Methods - Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 09-24-2009 |
20110027294 | Anti-Respiratory Syncytial Virus Antibodies, Antigens and Uses Thereof - Anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies, RSV F protein antigens and their uses are disclosed. | 02-03-2011 |
20110081355 | Methods of Diagnosing and Treating Conditions Using Anti-IL-6 Antibodies - Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma. | 04-07-2011 |
20120045453 | Anti-IL-6 Antibodies, Compositions, Methods and Uses - An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 02-23-2012 |
20130017208 | Anti-IL-6 Antibodies, Compositions, Methods and Uses - An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 01-17-2013 |
Patent application number | Description | Published |
20080221305 | Polynucleotides encoding novel adiponectin receptor variants - The present invention provides novel polynucleotides encoding human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 09-11-2008 |
20080274505 | Polynucleotide encoding a novel TRP channel family member, LTRPC3, and splice variants thereof - The present invention provides novel polynucleotides encoding LTRPC3 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of LTRPC3 polypeptides, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 11-06-2008 |
20080318257 | Polynucelotides encoding novel variants of the TRP channel family member, LTRPC3 - The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 12-25-2008 |
20090088385 | Antibodies that bind to BGS-4 - The present invention provides novel polynucleotides encoding BGS-4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides of the present invention. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 04-02-2009 |
20100035259 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 MODULATORS - VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer | 02-11-2010 |
20110104664 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICORTUBULE-STABILIZING AGENTS - Biomarkers that are useful for identifying a mammal that will respond therapeutically or is responding therapeutically to a method of treating cancer that comprises administering a microtubule-stabilizing agent. In one aspect, the cancer is breast cancer, and the microtubule-stabilizing agent is an epothilone or analog or derivative thereof, or ixabepilone. | 05-05-2011 |
Patent application number | Description | Published |
20090142727 | DEVICE FOR DELIVERING MEDICINAL IMPLANTS - The invention includes a device for inserting a medicament within a body cavity of a mammal, the device including a cartridge for containing the medicament therein, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen, a substantially stationary member disposed within the lumen of the retractable chamber and having a uniform cross-section sized to provide a sliding fit within the lumen to provide for retraction of the retractable chamber about the substantially stationary member upon actuation of the device, and means for retracting the retractable chamber about the substantially stationary member while maintaining the substantially stationary member in a substantially stationary position upon actuation of the device; the device further including means for activating the means for retracting the retractable chamber. | 06-04-2009 |
20090142728 | ACTUATORS FOR DEVICE FOR DELIVERING MEDICINAL IMPLANTS - The invention includes an actuator for actuating a device for inserting a medicament within a body cavity of a mammal, the actuator including a handle case having a proximal portion for gripping and a distal portion including means for attaching the actuator to a cartridge for containing medicament, and means for creating a proximal to distal linear motion with respect to the handle case, wherein the cartridge includes a retractable chamber for containing the medicament disposed therein, a substantially stationary member and means for retracting the retractable chamber about the substantially stationary member while maintaining the substantially stationary member in a substantially stationary position. | 06-04-2009 |
20090148500 | MEDICINAL IMPLANT CARTRIDGE - The invention includes a cartridge for use in a device for inserting a medicament within a body cavity of a mammal, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen having a uniform cross-section sized to contain the medicament therein, a substantially stationary member disposed within the lumen of the retractable chamber and having a uniform cross-section sized to provide a sliding fit within the lumen suitable to provide for retraction of the retractable chamber about the substantially stationary member upon actuation of the device; and means for retracting the retractable chamber about the substantially stationary member while maintaining the substantially stationary member in a substantially stationary position upon actuation of the device. | 06-11-2009 |
20100016257 | METHOD OF TREATMENT FOR OSTEOARTHRITIS BY LOCAL INTRA-ARTICULAR INJECTION OF MICROPARTICLES - A method of treatment of osteoarthritis is described, where a therapeutically effective amount of a composition having biodegradable microparticles in an aqueous vehicle is delivered into the intra-articular space of a joint. In one aspect, the microparticle-containing composition is injected into the synovial fluid-containing portion of an affected joint. | 01-21-2010 |
20100136502 | MEDICINAL IMPLANT DEVICE AND CARTRIDGE - The invention includes a device for inserting a medicament within a body cavity of a mammal, and a cartridge for containing the medicament within the device, where the cartridge includes a housing, a retractable chamber for containing medicament disposed within the housing, and a substantially stationary member disposed within the barrel of the retractable chamber, where upon activation of the device, the retractable chamber is retracted about the substantially stationary member, thereby depositing medicament within the body cavity. | 06-03-2010 |
20100240859 | Semi-Crystalline Absorbable Microspheres - The present invention is directed to absorbable microspheres comprising a copolymer formed from greater than 88 to about 99 mole percent ε-caprolactone or p-dioxanone, and about 1 to less than 12 mole percent of a different second monomer selected from the group consisting of glycolide, p-dioxanone, trimethylene carbonate and the lactides and combinations thereof, said microspheres having a particle size ranging from about 5 to 2,000 microns. Also described herein are a method for making such microspheres and formulations comprising such absorbable microspheres. | 09-23-2010 |
20110245764 | DEVICE FOR DELIVERING MEDICINAL IMPLANTS - A device for inserting a medicament within a body cavity of a mammal, the device including a cartridge for containing the medicament, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen sized to contain the medicament, a stationary member disposed within the lumen and having a sized to provide a sliding fit within the lumen to provide for retraction of the retractable chamber about the stationary member upon actuation of the device, and means for retracting the retractable chamber while maintaining the stationary member in a stationary position. The device further includes means for activating the means for retracting the retractable chamber. The device further includes an actuator, the actuator including a handle case having a proximal portion for gripping and a distal portion including means for attaching the actuator to a cartridge. | 10-06-2011 |
20120010561 | MEDICINAL IMPLANT DEVICE AND CARTRIDGE - The invention includes a device for inserting a medicament within a body cavity of a mammal, and a cartridge for containing the medicament within the device, where the cartridge includes a housing, a retractable chamber for containing medicament disposed within the housing, and a substantially stationary member disposed within the barrel of the retractable chamber, where upon activation of the device, the retractable chamber is retracted about the substantially stationary member, thereby depositing medicament within the body cavity. | 01-12-2012 |
20140093839 | MEDICINAL IMPLANT DEVICE AND CARTRIDGE - The invention includes a device for inserting a medicament within a body cavity of a mammal, and a cartridge for containing the medicament within the device, where the cartridge includes a housing, a retractable chamber for containing medicament disposed within the housing, and a substantially stationary member disposed within the barrel of the retractable chamber, where upon activation of the device, the retractable chamber is retracted about the substantially stationary member, thereby depositing medicament within the body cavity. | 04-03-2014 |